Menu Back to Combination-Products-and-Convergence-An-Overview-of-Clinical-Benefits-Regulatory-Issues-Manufacturing-Challenges

Overview

Continuing Education credit or Certificate Program units are not available for Archived Webinars


An estimated 30 percent of all new healthcare products under development today are combination products. Why? Because drugs, biologics and medical devices, when used alone, can only slow or stop the progression of disease or injury. In order to tackle the clinical problems of the future, these products will be combined (called combination products) to treat a wide range of diseases from heart attack and stroke to Alzheimer’s, cancer, diabetes and beyond! In fact, every area of medicine will benefit because we can potentially erase the damage of disease or injury not just stop it – that’s not the next evolutionary advance in medicine, that’s a revolutionary advance, a change in the ethos of how why approach medical problems.

Today, the best known example of a combination product is the drug-eluting stent. Other examples include companion diagnostics and antibody-drug conjugates but that’s just the beginning. What about delivering multiple drugs and biologics on a single device? And what if we apply these drugs and biologics to the device at the patient’s bedside based on that particular patient, i.e., personalized medicine? Or we use one combination product to deliver another combination product? In fact, the true scope of combination products is even broader and includes the emerging areas of therapeutic foods and consumer products as well. The possibilities are endless and the best is yet to come! The quintessential example of a combination product is what we are now doing in tissue engineering (a.k.a. regenerative medicine) and biomedical nanotechnology. During this webinar, participants will be exposed to a wide range of examples of combination products on the market, under development and on the drawing board.


This archived webinar will be available for purchase through December 31, 2014.

Who should attend?

This webinar is designed for:

  • Drug Development and R&D Professionals
  • Pharmaceutical and Medical device and Diagnostics Professionals
  • Regulatory, Clinical and Other Professionals Responsible for Developing Drug/Device Combinations and Companion Diagnostics
  • Regulatory Affairs Professionals

Learning objectives

At the conclusion of this webinar, participants should be able to:

  • Define combination products
  • Identify examples of combination products on the market, under development and on the drawing board

Contact us

Registration Questions
Customer Service Department
Phone: +1.888.257.6457 | +1.215.442.6100
Fax: +1.215.442.6199
CustomerService@diahome.org

Questions on Archived Webinar
Jessica Culp
DIA North America
Phone +1.215.442.6132
Fax +1.215.442.6199
Jessica.Culp@diahome.org